These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38906245)

  • 1. Hepatobiliary Infection after Transjugular Intrahepatic Portosystemic Shunt Creation in Patients with Prior Biliary Intervention: A Multi-Institution Retrospective Study.
    Ronald J; Bartlett D; Border L; Fickert J; Gaba RC; Kim J; Kord A; Lokken RP; Patel M; Pollard B; Ramsey MT; Yu H
    J Vasc Interv Radiol; 2024 Sep; 35(9):1323-1331.e3. PubMed ID: 38906245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transjugular intrahepatic portosystemic shunt creation may be associated with hyperplastic hepatic nodular lesions in the long term: an analysis of 18 pediatric and young adult patients.
    Woerner AJ; Shin DS; Chick JFB; Koo KSH; Hsu EK; Tang ER; Monroe EJ
    Pediatr Radiol; 2021 Jul; 51(8):1348-1357. PubMed ID: 33783576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Prior to Abdominal Operation: a Retrospective Analysis.
    Schmitz A; Haste P; Johnson MS
    J Gastrointest Surg; 2020 Oct; 24(10):2228-2232. PubMed ID: 31485902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Increased Mortality After TIPS Compared with Serial Large Volume Paracenteses in Patients with Higher Model for End-Stage Liver Disease Score and Refractory Ascites.
    Ronald J; Rao R; Choi SS; Kappus M; Martin JG; Sag AA; Pabon-Ramos WM; Suhocki PV; Smith TP; Kim CY
    Cardiovasc Intervent Radiol; 2019 May; 42(5):720-728. PubMed ID: 30603968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE; Darwish WM; Davies MG; Waldman DL
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Sarcopenia With Excess Adiposity Predicts Survival After Transjugular Intrahepatic Portosystemic Shunt Creation.
    Ronald J; Bozdogan E; Zaki IH; Kappus MR; Choi SS; Martin JG; Suhocki PV; Smith TP; Kim CY; Bashir MR
    AJR Am J Roentgenol; 2020 Jan; 214(1):200-205. PubMed ID: 31670594
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
    Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts.
    Shoreibah MG; Mahmoud K; Aboueldahab NA; Vande Lune P; Massoud M; Bae S; El Khudari H; Gunn AJ; Abdel Aal AK
    J Vasc Interv Radiol; 2019 Feb; 30(2):154-161. PubMed ID: 30717946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.
    Hausegger KA; Karnel F; Georgieva B; Tauss J; Portugaller H; Deutschmann H; Berghold A
    J Vasc Interv Radiol; 2004 Mar; 15(3):239-48. PubMed ID: 15028808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Helzberg JH; Dai R; Muir AJ; Wilder J; Lee TH; Martin JG; Kim CY; Ronald J
    J Vasc Interv Radiol; 2021 Jul; 32(7):950-960.e1. PubMed ID: 33663923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Transjugular Intrahepatic Portosystemic Shunt (Tips) Creation Using Fluency Versus Viatorr Stent-Grafts: A Single-Centre Retrospective Study.
    Wu HM; Huang SQ; Wan YM; Li YH; Xu Y
    Cardiovasc Intervent Radiol; 2022 May; 45(5):552-562. PubMed ID: 35274174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.
    Praktiknjo M; Abu-Omar J; Chang J; Thomas D; Jansen C; Kupczyk P; Schepis F; Garcia-Pagan JC; Merli M; Meyer C; Strassburg CP; Pieper CC; Trebicka J
    JHEP Rep; 2021 Jun; 3(3):100264. PubMed ID: 34013182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between serum markers and transjugular intrahepatic portosystemic shunt prognosis in patients with cirrhotic ascites.
    Hu XG; Yang XX; Lu J; Li G; Dai JJ; Wang JM; Deng Y; Feng R
    World J Gastrointest Surg; 2024 Feb; 16(2):481-490. PubMed ID: 38463353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement.
    Borentain P; Soussan J; Resseguier N; Botta-Fridlund D; Dufour JC; Gérolami R; Vidal V
    Diagn Interv Imaging; 2016 Jun; 97(6):643-50. PubMed ID: 26947721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of transjugular intrahepatic portosystemic shunt creation on intermediate-term model for end-stage liver disease score progression.
    Casadaban LC; Gabra MG; Parvinian A; Minocha J; Knuttinen MG; Bui JT; Gaba RC
    Transplant Proc; 2014 Jun; 46(5):1384-8. PubMed ID: 24935301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites.
    Harrod-Kim P; Saad WE; Waldman D
    J Vasc Interv Radiol; 2006 Oct; 17(10):1605-10. PubMed ID: 17057001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortality.
    Patel NH; Sasadeusz KJ; Seshadri R; Chalasani N; Shah H; Johnson MS; Namyslowski J; Moresco KP; Trerotola SO
    J Vasc Interv Radiol; 2001 Nov; 12(11):1279-84. PubMed ID: 11698626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk.
    Parvinian A; Shah KD; Couture PM; Minocha J; Knuttinen MG; Bui JT; Gaba RC
    J Vasc Interv Radiol; 2013 Jul; 24(7):941-6. PubMed ID: 23707226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt.
    Ahmed R; Santhanam P; Rayyan Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1226-7. PubMed ID: 26111072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.